At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
ATX-MS-1467drug
Likely dose
ATX-MS-1467 50 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and Its Effect on Immune Tolerance in Subjects With Relapsing Multiple Sclerosis
In Brief
A Phase 2 clinical trial evaluating ATX-MS-1467 for Multiple Sclerosis. Completed, enrolled 37 participants across 1 site.
Detailed Summary
This is a multi-center, open-label, single arm, baseline-controlled Phase 2a trial to evaluate the clinical and biological effects of ATX-MS-1467 in subjects with relapsing multiple sclerosis (MS) and to assess the maintenance of any such effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartFeb 2014
Primary CompletionApr 2016
TodayJul 2026
First PostedOct 31, 2013
Enrollment StartFeb 28, 2014
Primary CompletionApr 30, 2016
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.7 years ago
Interventions
ATX-MS-1467drug
Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.